Study Design: Participants who achieved average 20.9% weight loss on tirzepatide over 36 weeks were randomized to either: Continue tirzepatide Switch to placebo Results at 88 Weeks (52 weeks after randomization): Continued Tirzepatide: Additional 5.5% weight loss Total weight loss: 25.3% from baseline 89.5% maintained at least 80% of initial weight loss Switched to Placebo: 14% weight regain Total weight loss: 9.9% from baseline Only 16.6% maintained at least 80% of initial weight loss Key Takeaway: Continued treatment is essential for maintaining weight loss
This decision was made based on the benefits provided by the assay kit (ability to measure total GSH, free GSH, and GSSG within a single well) compared to other commercially available kits, and our prior positive results with this kit [15]
Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, et al
In laboratory studies, it acts as a selective agonist for the GLP-1 receptor
Because retatrutide is not a licensed medicine in the UK, there is no official manufacturer's guidance, patient information leaflet, or standardised reconstitution protocol approved by the MHRA
